References

1. https://adisinsight.springer.com/

2. https://www.business-standard.com/markets/news/astrazeneca-pharma-to-launch-copd-drug-in-january-2025-stock-up-3-124111900299_1.html 3. https://www.venturasecurities.com/news/stocks/copd-drug-launch-boosts-astrazeneca-stock-by-3/ 4. https://www.astrazeneca.com/content/dam/az/PDF/2022/fy/Full-year-and-Q4-2022-results-announcement.pdf 5. https://www.astrazeneca.com/content/dam/az/PDF/2021/full-year/Full-year-2021-results-announcement.pdf 6. https://www.astrazeneca.com/content/dam/az/PDF/2023/fy/Full-year-and-Q4-2023-results-announcement.pdf 7. https://otp.tools.investis.com/clients/uk/astrazeneca/rns/regulatory-story.aspx?cid=1343&newsid=1883997&culture=en-GB&val=638686508016774586 8.https://pubmed.ncbi.nlm.nih.gov/36883591/#:~:text=Gepotidacin%3A%20a%20novel%2C%20oral%2C,tract%20infections%20and%20urogenital%20gonorrhoea 9. https://www.pharmaceutical-technology.com/data-insights/gepotidacin-mesylate-gsk-net-present-value/#:~:text=The%20revenue%20for%20Gepotidacin%20Mesylate,net%20present%20value%20(NPV). 10. https://www.hcplive.com/view/5-fda-decisions-to-watch-in-q1-2025 11. https://www.veganmed.org/post/2025-anticipated-drug-approvals-key-new-treatments-to-watch 12. https://www.fiercepharma.com/marketing/eli-lilly-donanemab-approval-sight-runs-emotive-tv-spot-about-life-alzheimers#:~:text=Related,-'The%20Top%20Line&text=Talking%20on%20a%20quarterly%20results,in%20annual%20sales%20by%202028. 13. https://www.fiercepharma.com/marketing/eli-lilly-tipped-leapfrog-eisai-biogen-and-take-control-13b-alzheimers-market#:~:text=Related&text=Writing%20before%20the%20publication%20of,companies%20to%20leapfrog%20the%20incumbents. 14. https://www.biopharmadive.com/news/donanemab-leqembi-lilly-biogen-alzheimer-approval-analyst-view/718574/#:~:text=On%20the%20other%20hand%2C%20donanemab's,Jacob%20Bell%20contributed%20writing. 15. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional 16. https://www.biopharmadive.com/news/donanemab-leqembi-lilly-biogen-alzheimer-approval-analyst-view/718574/ 17. https://www.fool.com/investing/2024/01/01/why-eli-lilly-could-start-off-2024-with-a-bang/ 18. https://www.biospace.com/drug-development/vertex-dips-on-mixed-phase-ii-data-for-non-opioid-pain-therapy#:~:text=8%20voltage%2Dgated%20sodium%20channel,to%20the%20spine%20and%20brain. 19. https://news.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2024-financial-results 20. https://www.nature.com/articles/d41586-024-03943-9#:~:text=The%20pharmaceutical%20firm%20Eli%20Lilly,potentially%20cheaper%20than%20existing%20treatments 21. https://www.linkedin.com/pulse/orforglipron-new-kid-glp-1-block-lloyd-price-kkcje 22. https://www.chugai-pharm.co.jp/english/news/detail/20240222083000_1049.html#:~:text=We%20have%20a%20license%20agreement,the%20commercial%20success%20of%20orforglipron. 23. https://www.linkedin.com/pulse/can-eli-lillys-miracle-drug-drive-its-stock-new-heights-5r3of 24. https://www.pharmavoice.com/news/trial-readouts-2025-obesity-market-eli-lilly/736710/ 25. https://www.pharmavoice.com/news/trial-readouts-2025-obesity-market-eli-lilly/736710/ 26. https://investor.lilly.com/static-files/cdedba2e-c4a7-4047-9e61-4ac3b1e2cd73 27. https://www.pharmavoice.com/news/trial-readouts-2025-obesity-market-eli-lilly/736710/ 28. https://www.ajmc.com/view/postponed-mactel-treatment-approval-could-lead-to-delay-of-needed-care 29. https://www.cgtlive.com/view/nt-501-cell-therapy-slows-degeneration-macular-telangiectasia 30. https://www.neurologylive.com/view/fda-accepts-resubmitted-new-drug-application-migraine-treatment-axs-07 31. https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-january-2025 32. https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-january-2025 33. https://www.globenewswire.com/news-release/2025/01/13/3008327/0/en/Axsome-Therapeutics-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2024-Net-Revenue.html#:~:text=%E2%80%9CWe%20delivered%20strong%20revenue%20growth,of%20migraine%2C%20if%20approved.%E2%80%9D 34. https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/urinary-tract-infections-uti 35. https://www.sciencedirect.com/science/article/abs/pii/S0196655324005510 36. https://www.sciencedirect.com/science/article/abs/pii/S0196655324005510 37. https://link.springer.com/article/10.1007/s12126-024-09569-6 38. https://emedicine.medscape.com/article/233101-medication 39.https://pmc.ncbi.nlm.nih.gov/articles/PMC2034724/#:~:text=The%20reviewer%2C%20Annette%20Pohl%2C%20postdoctoral,careful%20supervision%20to%20guarantee%20compliance. 40. https://www.rghospitals.com/blog/the-crucial-importance-of-urinary-tract-infection-treatment#:~:text=Rapid%20Relief%20of%20Symptoms:%20UTIs,arise%20from%20an%20untreated%20infection. 41. https://www.medicalnewstoday.com/articles/drugs-bactrim-side-effects#more-common-side-effects 42.https://pmc.ncbi.nlm.nih.gov/articles/PMC9198803/#:~:text=Selected%20failed%20clinical%20trial%20examples,to%20initiation%20of%20the%20trial. 43. https://www.pharmaceutical-technology.com/news/eli-lillys-donanemab-wins-fda-approval-for-alzheimers-disease/#:~:text=The%20BLA%20for%20monthly%20IV%20maintenance%20dosing,Kisunla%20is%20expected%20to%20generate%20global%20sales 44. https://www.alzint.org/news-events/news/donanemab-update-new-alzheimers-disease-treatment-approved-by-the-fda/#:~:text=On%202%20July%202024%2C%20the,dementia%20stage%20of%20Alzheimer's%20disease. 45. https://www.upmc.com/services/pain-management/conditions/acute-pain 46. https://pubmed.ncbi.nlm.nih.gov/26778249/ 47.https://pubmed.ncbi.nlm.nih.gov/17640644/#:~:text=Background:%20Acute%20pain%20in%20the,injury%20treatment%20in%20the%20ED. 48.https://pubmed.ncbi.nlm.nih.gov/12160512/#:~:text=The%20patients%20with%20pain%20were,on%20health%20economy%20in%20general. 49.https://www.sciencedirect.com/science/article/pii/S1198743X14613239#:~:text=RESISTANCE%20OF%20UROPATHOGENS,bacilli%20and%20Gram%2Dpositive%20cocci. 50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3739462/#:~:text=CONCLUSIONS,from%20recurrent%20or%20chronic%20UTI. 51. https://pmc.ncbi.nlm.nih.gov/articles/PMC10058863/#:~:text=Abstract,intravesical%20administration%20route%20for%20antibiotics. 52. https://www.mayoclinic.org/diseases-conditions/obesity/symptoms-causes/syc-20375742#:~:text=Obesity%20is%20a%20complex%20disease,sleep%20apnea%20and%20certain%20cancers. 53. https://nam.edu/clinical-perspectives-on-obesity-treatment-challenges-gaps-and-promising-opportunities/#:~:text=This%20discussion%20paper%20highlights%20the,factors%20that%20cause%20severe%20obesity. 54. https://www.sciencedirect.com/science/article/abs/pii/S0953620507002701 55.https://pmc.ncbi.nlm.nih.gov/articles/PMC10729542/#:~:text=Barriers%20include%20insufficient%20self%2Dcontrol,social%20dynamics%20are%20also%20barriers. 56.https://pmc.ncbi.nlm.nih.gov/articles/PMC7789016/#:~:text=Cost,socioeconomic%20status%20in%20developed%20countries.&text=Other%20major%20obstacles%20include%20the,weight%20loss%20programs%20and%20gymnasiums.&text=In%20addition%2C%20unlike%20medical%20treatments,weight%20loss%20compared%20to%20HCPs.&text=Nevertheless%2C%20these%20factors%20can%20hinder,interventions%20and%20must%20be%20acknowledged. 57. https://www.med.umich.edu/1libr/Ophthalmology/Retina/RetinalTelangiectasia.pdf 58. https://www.asrs.org/patients/retinal-diseases/31/idiopathic-juxtafoveal-telangiectasis#:~:text=Symptoms,more%20common%20after%20age%2040 59. https://www.sciencedirect.com/topics/nursing-and-health-professions/retinal-telangiectasia#:~:text=Retinal%20telangiectasia%20refers%20to%20the,several%20other%20diseases%20and%20disorders. 60. https://www.mdfoundation.com.au/about-macular-disease/other-macular-conditions/macular-telangiectasia/#:~:text=Treatment,help%20prevent%20further%20vision%20loss. 61. https://migrainetrust.org/understand-migraine/types-of-migraine/ 62. https://www.ninds.nih.gov/health-information/disorders/migraine#toc-types-of-migraine 63. https://www.ninds.nih.gov/health-information/disorders/migraine#:~:text=A%20headache%20during%20a%20migraine,nausea%2C%20vomiting%2C%20or%20constipation. 64. https://www.mayoclinic.org/diseases-conditions/migraine-headache/symptoms-causes/syc-20360201#:~:text=A%20migraine%20is%20a%20headache,interferes%20with%20your%20daily%20activities.&text=For%20some%20people%2C%20a%20warning,and%20lifestyle%20changes%2C%20might%20help. 65. https://my.clevelandclinic.org/health/diseases/9638-chronic-migraine 66. https://www.uptodate.com/contents/acute-treatment-of-migraine-in-adults#:~:text=The%20abortive%20(symptomatic)%20therapy%20of,option%20that%20best%20describes%20you: 67. https://www.ninds.nih.gov/health-information/disorders/migraine#:~:text=Several%20medicines%20used%20to%20treat,types%20of%20headache%2C%20including%20migraine. 68. https://www.nhsinform.scot/illnesses-and-conditions/brain-nerves-and-spinal-cord/migraine-treatment-and-prevention/#:~:text=The%20non%2Dhormonal%20treatments%20that,the%20last%20day%20of%20bleeding. 69. https://www2.hse.ie/conditions/migraine/treatment-and-prevention/#:~:text=Painkillers%20for%20migraine,sick%20and%20cannot%20swallow%20anything 70. https://www.mayoclinic.org/diseases-conditions/copd/symptoms-causes/syc-20353679#:~:text=Chronic%20obstructive%20pulmonary%20disease%20(COPD,airflow%20is%20known%20as%20obstruction. 71. https://www.tandfonline.com/doi/full/10.1080/17476348.2024.2398639#d1e813 72. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)#:~:text=Some%20inhalers%20open%20the%20airways,or%20nebulised%20treatment%20as%20needed. 73. https://pmc.ncbi.nlm.nih.gov/articles/PMC8369747/#:~:text=3).-,Heavy%20financial%20burden%20of%20COPD,41). 74.https://www.tandfonline.com/doi/full/10.1080/17476348.2024.2398639#:~:text=In%20LMICs%2C%20the%20effective%20management,optimal%20COPD%20management%20in%20LMICs. 75.https://pmc.ncbi.nlm.nih.gov/articles/PMC8003143/#:~:text=VR%20therapy%20was%20revealed%20to,term%20effects%20of%20interrupted%20training. 76. https://journals.lww.com/lungindia/fulltext/2021/11000/what_is_the_true_burden_of_chronic_obstructive.1.aspx 77. https://www.biopharmadive.com/news/novo-nordisk-cagrisema-obesity-drug-study-results/735854/#:~:text=David%20Risinger%2C%20an%20analyst%20with,who%20got%20the%20single%20drugs 78. https://www.biopharmadive.com/news/obesity-glp-1-next-drug-development-biotech/714507/ 79. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-explore-cagrisema-weight-loss-potential-new-trial-2024-12-20/#:~:text=COPENHAGEN%2C%20Dec%2020%20(Reuters),disappointing%20late%2Dstage%20trial%20data 80. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight 81. https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity#:~:text=the%20above%20table-,Nearly%201%20in%203%20adults%20(30.7%25)%20are%20overweight.,(PDF%2C%2097.2%20KB)%20. 82. https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity 83. https://ourworldindata.org/obesity#:~:text=What%20is%20obesity?-,Obesity%20is%20commonly%20measured%20using%20the%20Body%20Mass%20Index%20(BMI,Read%20more%20in%20our%20article: 84. https://pmc.ncbi.nlm.nih.gov/articles/PMC8455012/#:~:text=Results:,%2C%20and%20gender%20(1.2). 85.https://pmc.ncbi.nlm.nih.gov/articles/PMC2901890/#:~:text=Macular%20telangiectasia%20type%202%20was,type%202%20requires%20further%20study. 86. https://www.retinalphysician.com/issues/2024/march/neovascularization-in-macular-telangiectasia/#:~:text=Macular%20telangiectasia%20type%202%20is,described%20as%20its%20primary%20cause. 87. https://pmc.ncbi.nlm.nih.gov/articles/PMC3638089/ 88. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)#:~:text=Some%20inhalers%20open%20the%20airways,or%20nebulised%20treatment%20as%20needed. 89. https://pmc.ncbi.nlm.nih.gov/articles/PMC8369747/#:~:text=3).-,Heavy%20financial%20burden%20of%20COPD,41). 90.https://www.tandfonline.com/doi/full/10.1080/17476348.2024.2398639#:~:text=In%20LMICs%2C%20the%20effective%20management,optimal%20COPD%20management%20in%20LMICs. 91. https://journals.lww.com/lungindia/fulltext/2021/11000/what_is_the_true_burden_of_chronic_obstructive.1.aspx 92.https://www.ncbi.nlm.nih.gov/books/NBK470195/#:~:text=An%20uncomplicated%20urinary%20tract%20infection,seek%20therapy%20for%20symptom%20relief. 93. https://www.medicalnewstoday.com/articles/complicated-vs-uncomplicated-uti#:~:text=than%20complicated%20cases.-,Uncomplicated%20UTIs,6%20months%20of%20the%20infection. 94.https://www.aafp.org/pubs/afp/issues/2005/0801/p451.html#:~:text=Uncomplicated%20UTI%20occurs%20in%20patients,CFU)%20per%20mL%20of%20urine. 95. https://www.ncbi.nlm.nih.gov/books/NBK568701/#:~:text=Introduction,Go%20to: 96. https://www.goodrx.com/conditions/urinary-tract-infection/complicated-uncomplicated-uti#:~:text=And%20finally%2C%20an%20uncomplicated%20UTI,and%20around%20the%20genital%20area. 97. https://www.aafp.org/pubs/afp/issues/2024/0200/acute-uncomplicated-utis-adults.html#:~:text=An%20acute%20uncomplicated%20urinary%20tract,uncomplicated%20UTI%20without%20further%20testing. 98. https://my.clevelandclinic.org/health/diseases/23912-hemophilia-b 99. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-021-00760-4#:~:text=Mainstay%20haemophilia%20treatment%2C%20namely%20intravenous,potentially%20circumvent%20the%20aforementioned%20challenges. 100. https://www.ajmc.com/view/ace0024_mar15_hemophilia_bauer 101.https://pmc.ncbi.nlm.nih.gov/articles/PMC6142469/#:~:text=However%2C%20development%20of%20neutralizing%20antibodies,of%20patients%20with%20hemophilia%20B.&text=Inhibitors%20significantly%20increase%20the%20cost,episodes%20more%20difficult%20to%20treat.&text=Despite%20the%20development%20of%20multiple,patients%20with%20hemophilia%20and%20inhibitors. 102. https://pmc.ncbi.nlm.nih.gov/articles/PMC3262316/#:~:text=*%20Costs%20of%20coagulation%20factor%20concentrates%20(prohibitive,problems%20(difficult%20access%20to%20hemophilia%20treatment%20centers 103. https://www.mayoclinic.org/diseases-conditions/cystic-fibrosis/symptoms-causes/syc-20353700#:~:text=A%20cough%20that%20won't,Repeated%20sinus%20infections. 104.https://pmc.ncbi.nlm.nih.gov/articles/PMC4967225/#:~:text=Among%20Caucasians%2C%20CF%20occurs%20in,each%20year%20(Figure%201). 105. https://www.news-medical.net/health/Cystic-Fibrosis-Epidemiology.aspx#:~:text=Cystic%20fibrosis%20is%20rare%20among,000%20to%201:350%20000. 106. https://www.fixhealth.com/blogs/cystic-fibrosis-causes-symptoms-diagnosis-and-treatment-in-india 107. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-trikafta#:~:text=TRIKAFTA%20may%20cause%20serious%20side,rash%20and%20elevated%20liver%20enzymes. 108.https://pmc.ncbi.nlm.nih.gov/articles/PMC5586905/#:~:text=Three%20particularly%20important%20areas%20of,numerous%20new%20therapies%20leading%20to 109. https://www.biospace.com/fda/vertex-wins-fda-approval-for-new-cystic-fibrosis-option-but-stock-still-down 110. https://www.sciencedirect.com/topics/nursing-and-health-professions/hyperlipoproteinemia-type-1#:~:text=Hyperlipoproteinemia%20Type%20I%2C%20also%20known,Management%20typically%20involves%20dietary%20modifications. 111. https://www.sciencedirect.com/topics/medicine-and-dentistry/type-1-hyperlipidemia#:~:text=Type%20I%20hyperlipidemia%2C%20or%20familial,without%20an%20increase%20in%20VLDL. 112. https://pmc.ncbi.nlm.nih.gov/articles/PMC6752750/ 113. https://www.nhs.uk/medicines/atorvastatin/side-effects-of-atorvastatin/ 114. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tryngolza#:~:text=Original%20Approval%20date:%20December%2019%2C%202024 115. https://ir.ionis.com/news-releases/news-release-details/ionis-enters-new-chapter-2025-commercial-stage-biotech-multiple#:~:text=Launch%20TRYNGOLZA%2C%20Ionis'%20first%20independent,in%20second%20half%20of%202025 116. https://www.statnews.com/2024/12/19/ionis-fda-approval-tryngolza-familial-chylomicronemia-syndrome-triglycerides/ 117.https://pubmed.ncbi.nlm.nih.gov/29342279/#:~:text=Results:%20Among%2023%20477%20patients,substantially%20increased%20risk%20of%20PTLD. 118. https://assets.publishing.service.gov.uk/media/5a7de30240f0b65d8b4e419d/chronic_lymphoproliferative_disorders.pdf 119. https://www.myast.org/uploads/files/general/13.-Post-Transplant-Lymphoproliferative-Disorder-2024.pdf 120.https://www.sciencedirect.com/science/article/abs/pii/S2152265022015646#:~:text=Context:%20Chronic%20lymphoproliferative%20disorders%20(CLPD,the%20development%20of%20these%20diseases. 121. https://www.myast.org/uploads/files/general/13.-Post-Transplant-Lymphoproliferative-Disorder-2024.pdf 122.https://pmc.ncbi.nlm.nih.gov/articles/PMC3100685/#:~:text=The%20overall%20median%20age%20was,classified%20as%20EBV+%20mucocutaneous%20ulcer. 123. https://ashpublications.org/blood/article/142/17/1426/497352/How-I-treat-posttransplant-lymphoproliferative#:~:text=Posttransplant%20lymphoproliferative%20disorder%20(PTLD)%20is,of%20therapy%20in%20the%20future. 124. https://ashpublications.org/blood/article/126/20/2274/103859/How-I-treat-posttransplant-lymphoproliferative 125. https://my.clevelandclinic.org/health/diseases/lymphoproliferative-disorders#:~:text=Symptoms%20and%20Causes&text=The%20symptoms%20vary%20widely%20depending,Unexplained%20weight%20loss. 126. https://www.medicalnewstoday.com/articles/lymphoproliferative-disorders 127.https://pmc.ncbi.nlm.nih.gov/articles/PMC2774540/#:~:text=Risk%20factors%20include%20the%20degree,%2Dhost%20disease%20(GVHD).&text=Although%20the%20proliferating%20B%20cells,persisting%20recipient%2Dderived%20B%20cells.&text=In%20recipients%20of%20SOTs%2C%20the,from%20an%20EBV%2Dseropositive%20donor.&text=Most%20PTLD%20occurs%20in%20the,negative%20and%20have%20cytogenetic%20abnormalities. 128.https://pmc.ncbi.nlm.nih.gov/articles/PMC10390257/#:~:text=PTLD%20After%20Allogeneic%20Hematopoietic%20Stem,an%20increased%20risk%20of%20GVHD. 129.https://pmc.ncbi.nlm.nih.gov/articles/PMC9740763/#:~:text=Symptoms%20may%20include%20fatigue%2C%20malaise,poor%20%5B46%2C48%5D. 130. https://www.sciencedirect.com/topics/immunology-and-microbiology/lymphoproliferative-disorders#:~:text=prognosis%20is%20poor.-,Treatment,prednisone%2C%20adriamycin%2C%20and%20vincristine. 131. https://www.businesswire.com/news/home/20250116967931/en/Atara-Biotherapeutics-Provides-Regulatory-and-Business-Update-on-EBVALLOTM-tabelecleucel 132. https://investors.atarabio.com/news-events/press-releases/detail/329/atara-biotherapeutics-announces-expanded-global-tab-cel 133. https://investors.atarabio.com/news-events/press-releases/detail/364/atara-biotherapeutics-announces-third-quarter-2024 134. https://www.biopharmadive.com/news/novartis-entresto-sales-acceleration-uptake-jefferies/442727/#:~:text=Heart%2Dfailure%20drug%20Entresto%20has,$200%20million%20Novartis%20had%20forecast. 135. https://www.reuters.com/article/markets/europe/novartis-sees-entresto-sales-peak-between-4-bln-and-5-bln-idUSZ8N15A01M/#:~:text=A%20senior%20Novartis%20executive%20%22sees%20a%20path%22,finally%20hit%20the%20company's%20internal%202017%20target. 136. https://www.fiercepharma.com/pharma/novartis-narasimhan-wraps-up-eventful-first-year-as-ceo-rosy-outlook-planned#:~:text=For%202018%2C%20Entresto%20sales%20hit,to%20read%20out%20in%202019. 137. https://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement#:~:text=Entresto%20is%20already%20approved%20to,$1%20billion%20in%202018%20revenues. 138. https://pmlive.com/pharma_news/cosentyx_entresto_drive_topline_growth_for_novartis_in_q4_1323659/ 139. https://www.novartis.com/sites/novartiscom/files/q1-2019-media-release-en.pdf 140. https://www.novartis.com/sites/novartiscom/files/q3-2019-media-release-en.pdf 141. https://pmlive.com/pharma_news/cosentyx_entresto_drive_topline_growth_for_novartis_in_q4_1323659/ 142. https://www.globaldata.com/data-insights/healthcare/the-global-drug-sales-of-entresto-1127386/ 143. https://www.fiercepharma.com/pharma/novartis-entresto-falls-short-post-heart-attack-trial#:~:text=That%20indication%20could%20boost%20Entresto's,Entresto%20Novartis%20U.S.%20FDA%20Pharma 144. https://www.fiercepharma.com/pharma/novartis-takes-entresto-generic-fight-fda-again-after-similar-appeal-flopped-april#:~:text=Novartis%20has%20long%20held%20that,its%20most%20recent%20annual%20report. 145. https://www.novartis.com/news/media-releases/novartis-maintains-growth-momentum-and-confirms-fy22-group-guidance 146. https://www.reuters.com/business/healthcare-pharmaceuticals/us-appeals-court-lifts-pause-generic-version-novartis-entresto-2025-01-16/#:~:text=Entresto%20is%20Switzerland%2Dbased%20Novartis,invalidated%20one%20of%20the%20patents. 147. https://www.novartis.com/investors/financial-data/product-sales 148. https://www.reuters.com/business/healthcare-pharmaceuticals/us-appeals-court-lifts-pause-generic-version-novartis-entresto-2025-01-16/#:~:text=Entresto%20is%20Switzerland%2Dbased%20Novartis,would%20immediately%20block%20the%20generic. 149. https://www.fiercepharma.com/pharma/novartis-loses-bid-thwart-launch-msns-entresto-generic-now#:~:text=During%20its%20latest%20earnings%20call,FDA%20approval%20heart%20failure%20Pharma 150. https://www.statista.com/statistics/263787/revenues-of-bayers-top-pharmaceutical-products/ 151. https://pmc.ncbi.nlm.nih.gov/articles/PMC5906253/ 152. https://ddd.uab.cat/pub/infanu/22078/iaBAYERa2012ieng.pdf 153. https://www.bayer.com/sites/default/files/2020-05/ar-2014.pdf 154. https://www.bayer.com/sites/default/files/2020-05/ar-2014.pdf 155. https://www.pharmacompass.com/radio-compass-blog/top-drugs-by-sales-revenue-in-2015-who-sold-the-biggest-blockbuster-drugs 156. https://www.genengnews.com/a-lists/the-top-15-best-selling-drugs-of-2016/ 157. https://www.biopharmadive.com/news/competition-and-doughnut-hole-discount-takes-toll-on-xarelto-sales/553269/#:~:text=Johnson%20%26%20Johnson's%20U.S.%2Dbased%20sales,quarter%202018%20to%20%24542%20million. 158. https://www.fiercepharma.com/special-report/top-15-pharma-companies-by-2018-revenue 159. https://www.fiercepharma.com/special-report/top-20-drugs-by-global-sales-2019#:~:text=Xarelto,-Xarelto&text=Xarelto%20hit%20%246.35%20billion%20in,the%20drug%20goes%20off%20patent. 160. https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales#:~:text=Xarelto,-As%20Bayer%20and&text=Altogether%2C%20Xarelto%20generated%20around%20%246.93,billion%20it%20hit%20in%202019. 161. https://www.statista.com/statistics/263787/revenues-of-bayers-top-pharmaceutical-products/#:~:text=Bayer%20AG%20is%20an%20international,companies%20to%20develop%20new%20drugs. 162. https://www.reuters.com/article/business/bayer-jj-settle-thousands-of-us-xarelto-lawsuits-for-775-million-idUSKCN1R61UD/#:~:text=Xarelto%20is%20Bayer's%20best%2Dselling,offset%20by%20product%20liability%20insurance. 163. https://www.fiercepharma.com/pharma/bayers-pharma-sector-feels-effects-xarelto-generics-china#:~:text=Xarelto's%20decline%20contributed%20to%20rough,launch%20trajectory%2C%E2%80%9D%20Olerich%20said. 164. https://www.pharmavoice.com/news/drug-patent-expirations-xarelto-abilify-victoza/713384/ 165.https://www.drugpatentwatch.com/p/tradename/XARELTO#:~:text=The%20patents%20for%20XARELTO%20are,patent%20expiry%20environment%5B1%5D. 166. https://www.forbes.com/sites/maryroeloffs/2023/08/29/these-10-medications-targeted-for-lower-costs-by-white-house/ 167. https://www.pharmavoice.com/news/drug-patent-expirations-xarelto-abilify-victoza/713384/ 168.https://www.drugpatentwatch.com/p/tradename/XARELTO#:~:text=Xarelto%20was%20eligible%20for%20patent,were%20$7.2bn%20in%202020) 169. https://www.juve-patent.com/cases/why-bayer-is-fighting-so-hard-for-xarelto/ 170. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-and-full-year-2016-results 171. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2017-revenue#:~:text=For%20the%20full%20year%202017,increased%20volume%20in%20several%20countries. 172.https://www.medicalnewstoday.com/articles/326007#:~:text=Jardiance%20contains%20the%20drug%20empagliflozin,taken%20by%20mouth%20once%20daily. 173. https://www.boehringer-ingelheim.com/us/media/press-releases/jardiance-empagliflozin-lessened-risk-heart-failure-boehringer-ingelheim-us#:~:text=Its%20research%20efforts%20are%20focused%20on%20diseases,of%20around%20$20.7%20billion%20(17.5%20billion%20euros). 174. https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jardiancer-empagliflozin-tablets-reduce-risk#:~:text=JARDIANCE%20is%20marketed%20by%20Boehringer,Company%20(%20NYSE%20:%20LLY). 175. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2019-financial#:~:text=The%20company's%20worldwide%20Jardiance%20revenue,portion%20of%20Jardiance's%20gross%20margin. 176. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2020-financial#:~:text=For%20the%20full%20year%202020,driven%20primarily%20by%20increased%20volume. 177. https://www.business-standard.com/article/news-cm/lupin-receives-usfda-tentative-approval-for-empagliflozin-tablets-120080400887_1.html 178. https://www.fiercepharma.com/asia/jardiance-sparks-boehringer-ingelheims-2021-sales-potential-much-more-growth-2022 179. https://www.boehringer-ingelheim.com/mea/about-us/corporate-profile/boehringer-ingelheim-reaches-more-patients-ever-2022-innovative-medicines-drive-growth#:~:text=Significant%20growth%20in%20Human%20Pharma,of%2039.1%20percent%20in%202022. 180. https://www.fiercepharma.com/pharma/boehringer-ingelheim-and-eli-lillys-jardiance-get-big-lift-heart-failure-indications 181. https://xtalks.com/top-15-diabetes-drugs-in-2023-by-2022-sales-statistics-3715/#:~:text=2.,for%20a%20one%2Dmonth%20supply 182. https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline#:~:text=Human%20Pharma%20portfolio%20shows%20strong,more%20than%201%20billion%20people. 183. https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/ 184. https://www.fiercepharma.com/pharma/boehringer-ingelheim-sees-jardiance-growth-ahead-potential-us-chronic-kidney-disease-nod 185. https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report#:~:text=Empagliflozin%2C%20Dapagliflozin%20And%20Canagliflozin%20Market%20Size%202025%20And%20Growth%20Rate,in%20focus%20on%20personalized%20medicine. 186. https://www.mmm-online.com/home/channel/payers-managed-markets/novartis-says-slow-entresto-sales-due-to-limited-access/ 187. https://www.pharmaceutical-technology.com/news/novartis-plans-appeal-to-ward-off-entresto-generics/?cf-view 188. https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021#:~:text=J&J%2C%20which%20markets%20the%20drug,Xarelto%20patent%20expires%20in%202039. 189. https://www.fiercepharma.com/pharma/bayers-pharma-sector-feels-effects-xarelto-generics-china 190. https://www.fiercepharma.com/pharma/bayers-xarelto-squeeze-rolls-china-cancer-newcomer-nubeqa-continues-pick-steam#:~:text=Bayer's%20Xarelto%20squeeze%20rolls%20on%20as%20cancer%20newcomer%20Nubeqa%20gains%20steam&text=After%20a%20tough%20showing%20earlier,revenues%2C%20a%207%25%20increase. 191. https://pharmashots.com/14399/top-performing-drug-of-2021-%E2%80%93-xarelto-november-edition 192. https://www.bayer.com/sites/default/files/2024-03/q4fy-2023-2024-05-03-presentation-charts-en.pdf 193. https://www.bayer.com/sites/default/files/2024-11/bayer-quarterly-statement-q3-2024.pdf 194. https://www.reuters.com/business/bayer-sees-lower-2023-operating-profit-cost-inflation-2023-02-28/ 195. https://www.jnj.com/media-center/press-releases/fda-approves-xarelto-rivaroxaban-to-reduce-the-risk-of-stroke-and-systemic-embolism-in-patients-with-nonvalvular-atrial-fibrillation#:~:text=November%204%2C%202011,need%20for%20routine%20blood%20monitoring. 196. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000TOC.cfm 197. https://pubmed.ncbi.nlm.nih.gov/21164526/#:~:text=Abstract,anticoagulants%20in%20advanced%20clinical%20development. 198. https://www.fiercebiotech.com/biotech/bayer-s-xarelto-approved-canada#:~:text=Leverkusen%2C%20Germany%20/%20Toronto%2C%20Canada,Investigator%20for%20the%20RECORD%20program. 199. https://www.statista.com/statistics/1092916/major-diabetes-drugs-by-sales/ 200. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2018-financial 201. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2020-financial#:~:text=For%20the%20full%20year%202020,million%20%2C%20driven%20by%20increased%20volume. 202. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-solid-fourth-quarter-and-full-year-2021-financial#:~:text=For%20the%20full%20year%20of,primarily%20driven%20by%20increased%20demand. 203. https://www.boehringer-ingelheim.com/us/boehringer-ingelheim-reaches-more-patients-ever-2022-innovative-medicines-drive-growth#:~:text=JARDIANCE%C2%AE%2C%20which%20is%20used,of%2039.1%20percent%20in%202022. 204. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2017/annualreport2017.pdf 205. https://investors.niox.com/wp-content/uploads/2017/06/Circassia_transaction_RNS.pdf 206. https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2017/annualreport2017.pdf 207. https://www.pharmacompass.com/sales-forecast/tudorza-pressair 208. https://www.astrazeneca.com/content/dam/az/PDF/2019/q3/Year-to-date_and_Q3_2019_Results_announcement.pdf 209. https://www.astrazeneca.com/content/dam/az/PDF/2020/full-year/Full-year_2020_results_announcement.pdf 210. https://www.astrazeneca.com/content/dam/az/PDF/2021/full-year/Full-year-2021-results-announcement.pdf 211. https://www.sec.gov/Archives/edgar/data/38074/000003807413000014/forest10k2013.htm 212. https://www.sec.gov/Archives/edgar/data/38074/000003807414000019/forest10k2014.htm 213. https://www.pharmamanufacturing.com/home/article/55249347/key-drugs-losing-patent-protection-in-2025#:~:text=3.,Covis%20Pharma's%20Tudorza%20Pressair&text=Tudorza%20Pressair%2C%20(aclidinium%20bromide),Duaklir%20amounted%20to%20$143%20million. 214. https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-to-transfer-rights-to-eklira-duaklir.html#! 215.https://covispharma.com/index.php/products/#:~:text=Tudorza%C2%AE%20and%20Duaklir%C2%AE,trademarks%20of%20Covis%20Pharma%20GmbH. 216. https://www.astrazeneca.com/media-centre/press-releases/2014/duaklir-genuiar-approved-european-union-chronic-obstructive-pulmonary-disease-24112014.html# 217. https://www.astrazeneca.com/media-centre/press-releases/2014/duaklir-genuiar-approved-european-union-chronic-obstructive-pulmonary-disease-24112014.html#modal-historic-confirmation 218. https://www.ema.europa.eu/en/medicines/human/EPAR/duaklir-genuair#:~:text=Other%20information%20about%20Duaklir%20Genuair,contact%20your%20doctor%20or%20pharmacist. 219. https://www.pharmacompass.com/sales-forecast/tudorza-pressair) (https://www.astrazeneca.com/content/dam/az/our-company/our-company-052017/investor-relations/presentations-and-webcast/NewIR/Full_Year_and_Q4_2016_Results_announcement.pdf 220. https://www.astrazeneca.com/content/dam/az/our-company/our-company-052017/investor-relations/presentations-and-webcast/2016/Fourth%20quarter%20and%20Full-Year%20results%202015%20press%20release.pdf 221. https://www.astrazeneca.com/content/dam/az/PDF/2020/full-year/Full-year_2020_results_announcement.pdf 222. https://covispharma.com/index.php/covis-pharma-announces-positive-topline-results-from-the-avant-phase-3-clinical-trial-showing-significant-improvement-in-patients-with-moderate-to-severe-stable-copd/ 223. https://www.boehringer-ingelheim.com/us/media/boehringer-ingelheim-reports-strong-growth-2023-and-accelerates-late-stage-pipeline#:~:text=Boehringer%20Ingelheim%20reports%20strong%20growth%20in%202023,to%20USD%206.3%20bn%20(EUR%205.8%20bn) 224. https://www.pharmaceutical-technology.com/news/jardiance-and-ofev-propel-boehringers-human-pharma-sales/#:~:text=Last%20year%2C%20Jardiance%20propelled%20the,to%20cause%20endothelial%20cell%20death. 225. https://www.reuters.com/business/healthcare-pharmaceuticals/boehringers-profit-up-14-jardiance-gains-offset-impairments-2023-03-29/ 226. https://www.boehringer-ingelheim.com/about-us/who-we-are/2024-half-year-results-innovation-progress#:~:text=Net%20sales%20rose%20by%207.4,NEXGARD%C2%AE%20in%20Animal%20Health. 227. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2024-financial-results-and-raises#:~:text=For%20Q1%202024%2C%20the%20company's,%25%2C%20driven%20by%20increased%20volume. 228. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-first-quarter-2024-financial-results-and-raises#:~:text=For%20Q1%202024%2C%20the%20company's,%25%2C%20driven%20by%20increased%20volume. 229. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q2-2024-financial-results-raises-full-year-revenue#:~:text=For%20Q2%202024%2C%20the%20company's,%25%2C%20driven%20by%20increased%20volume. 230. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-q3-2024-financial-results-highlighted-strong#:~:text=For%20Q3%202024%2C%20the%20company's,partially%20offset%20by%20increased%20demand. 231. https://www.prnewswire.com/news-releases/lilly-reports-q3-2024-financial-results-highlighted-by-strong-volume-driven-revenue-growth-from-new-products-302290841.html 232. https://investor.lilly.com/static-files/cdedba2e-c4a7-4047-9e61-4ac3b1e2cd73 233. https://view.news.eu.nasdaq.com/view?id=b2a9e9cc5a21f6884181326d856ef3e15&lang=en 234. https://www.astrazeneca.com/content/dam/az/PDF/2019/full-year/Full-year_and_Q4_2019_results_announcement.pdf 235. https://www.almirall.com/documents/portlet_file_entry/4257831/Financial+Results_Business+Update_Q1+2024_vFinal.pdf/88c9924d-ef01-14fd-61d7-2621fea7b1bd 236. https://pmc.ncbi.nlm.nih.gov/articles/PMC4899342/#:~:text=The%20impending%20patent%20cliff%20is,(Denoon%20and%20Vollebregt%202010). 237. https://pmc.ncbi.nlm.nih.gov/articles/PMC6132437/#:~:text=Drug%20prices%20decrease%20significantly%20after,greatly%20between%20products%20and%20countries. 238. https://www.biospace.com/business/novartis-eyes-more-bolt-on-deals-in-2025-as-q4-earnings-easily-beat-consensus#:~:text=For%20the%20full%20year%202024,bring%20in%20nearly%20$2.2%20billion. 239. https://www.biospace.com/business/novartis-eyes-more-bolt-on-deals-in-2025-as-q4-earnings-easily-beat-consensus#:~:text=For%20the%20full%20year%202024,bring%20in%20nearly%20$2.2%20billion. 240.https://firstwordpharma.com/story/5911429#:~:text=Xarelto%20is%20already%20facing%20generic,see%20from%20our%20launch%20products.%22 241. https://investors.vrtx.com/static-files/2b8b5989-a5ff-456a-8bf7-1709028d5f20 242. https://ash.confex.com/ash/2024/webprogram/Paper198159.html

243. https://www.neurologylive.com/view/fda-approves-vertex-pharmaceuticals-suzetrigine-acute-pain-management

244. https://www.rheumatologyadvisor.com/news/journavx-a-nonopioid-oral-pain-medication-gets-fda-approval/

245. https://investors.vrtx.com/static-files/2b8b5989-a5ff-456a-8bf7-1709028d5f20

246. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain

247. https://www.usatoday.com/story/news/health/2025/01/31/fda-approves-new-non-opioid-pain-medication-journavx/78079113007/

248. https://www.managedhealthcareexecutive.com/view/fda-approves-journavx-as-a-new-non-opioid-pain-med-for-acute-pain-relief

249. https://www.goodrx.com/conditions/pain/opioid-alternatives

250. https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-vx-548-phase-3-program

251. https://investor.lilly.com/news-releases/news-release-details/lilly-reports-full-q4-2024-financial-results-and-provides-2025

252. https://www.wsj.com/business/novo-nordisk-shares-fall-after-latest-cagrisema-obesity-drug-trial-results-ba52ba81?mod=pharma_news_article_pos2

253. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-trial-with-next-gen-obesity-drug-diabetics-shows-157-weight-2025-03-10/

254. https://www.cnbc.com/2025/03/10/novo-nordisk-shares-fall-after-cagrisema-weight-loss-drug-trial-result.html

255. https://www.globenewswire.com/news-release/2025/03/10/3039539/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-the-REDEFINE-2-trial.html

256.https://firstwordpharma.com/story/5939890#:~:text=Meanwhile%2C%20revenue%20from%20Xarelto%20slipped%2014.7%%20in,decline%20for%20Xarelto%20will%20accelerate%20further%2C%20although

257. https://www.business-standard.com/markets/capital-market-news/alkem-laboratories-launches-generic-empagliflozin-in-india-125031200270_1.html

258. https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/diabetic-patients-get-price-relief-as-indian-brands-launch-generic-versions-of-empagliflozin/118924714#:~:text=Meanwhile%2C%20Glenmark%20Pharma%20announced%2C%20%E2%80%9C,based%20Eli%20Lilly%20and%20Company.

259. https://www.indiatoday.in/health/story/mankind-pharma-alkem-launch-low-cost-generic-version-popular-diabetes-drug-empagliflozin-2692544-2025-03-12

260. https://www.pharmabiz.com/NewsDetails.aspx?aid=176796&sid=2#:~:text=Mankind%20Pharma%20has%20launched%20its,Ingelheim%20under%20brand%20name%20Jardiance.

261. https://www.angelone.in/news/mankind-pharma-alkem-and-glenmark-launch-low-cost-diabetes-drug-prices-drop-90-percent

262. https://www.unibestpharm.com/Drug-Patent-Exclusivity-Expiration-Report-Week-of-Feb-10-2025-id45692036.html

263. https://www.businesstoday.in/industry/pharma/story/eli-lilly-aims-to-introduce-alzheimers-drug-donanemab-in-india-by-2025-ceo-dave-ricks-419502-2024-02-29

264.https://legal.economictimes.indiatimes.com/news/corporate-business/astrazeneca-to-launch-breztri-aerosphere-for-copd-treatment-following-dcgi-approval/115424660#:~:text=Published%20On%20Nov%2018%2C%202024,obstructive%20pulmonary%20disease%20(COPD).

265.https://www.indianpharmapost.com/drug-approval/astrazeneca-pharma-india-receives-permission-from-cdsco-to-import-new-drug-14966

266. https://ir.ionis.com/news-releases/news-release-details/tryngolzatm-olezarsen-approved-us-first-ever-treatment-adults#:~:text=Release%20Details-,TRYNGOLZA%E2%84%A2%20(olezarsen)%20approved%20in%20U.S.%20as%20first%2Dever,December%2019%2C%202024

267. https://investors.atarabio.com/news-events/press-releases/detail/370/atara-biotherapeutics-announces-fourth-quarter-and-full

268. https://finance.yahoo.com/news/atara-biotherapeutics-provides-clinical-programs-123000959.html

269.https://www.taro.ca/en/now-available-taro-rivaroxaban-generic-alternative-xarelto%C2%AE

270.https://www.tabletscapsules.com/3639-News/618158-FDA-Approves-First-Generics-to-Bayer-Blockbuster-Anticoagulant/#:~:text=Taro%20Pharmaceuticals%20and%20Lupin%20have%20received%20U.S.,2.5%20mg%20generic%20rivaroxaban%20tablets%20were%20approved

271.https://pharmaphorum.com/news/fda-approves-first-generics-anticoagulant-xarelto#:~:text=The%20US%20regulator%20has%20cleared,generic%20and%20brand%20name%20drugs.

272.https://www.lupin.com/lupin-launches-rivaroxaban-tablets-usp-2-5mg-in-the-united-states/#:~:text=Rivaroxaban%20Tablets%20USP%2C%202.5%20mg%2C%20is%20bioequivalent%20to%20Xarelto%C2%AE,with%20coronary%20artery%20disease%20(CAD)

273. https://www.gsk.com/en-gb/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/#:~:text=Blujepa%20is%20the%20first%20in,Staphylococcus%20saprophyticus%20and%20Enterococcus%20faecalis.

274. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or

Pharma Insight Reports

https://adisinsight.springer.com/pharma-insight-reports